Jefferies Financial Group Inc. Purchases 12,824 Shares of Labcorp Holdings Inc. $LH

Jefferies Financial Group Inc. grew its position in Labcorp Holdings Inc. (NYSE:LH) by 221.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,624 shares of the medical research company’s stock after purchasing an additional 12,824 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Labcorp were worth $4,672,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Labcorp by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company’s stock worth $2,471,326,000 after acquiring an additional 37,197 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of Labcorp by 20.0% in the 3rd quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company’s stock worth $756,878,000 after buying an additional 440,224 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Labcorp by 10.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,204,276 shares of the medical research company’s stock worth $554,728,000 after buying an additional 207,962 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Labcorp by 15.9% in the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock valued at $604,488,000 after acquiring an additional 289,029 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of Labcorp by 4.0% in the third quarter. Bank of America Corp DE now owns 726,090 shares of the medical research company’s stock valued at $208,431,000 after acquiring an additional 27,879 shares during the period. Institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling at Labcorp

In other news, CEO Adam H. Schechter sold 8,705 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the completion of the sale, the chief executive officer owned 80,773 shares of the company’s stock, valued at $22,613,209.08. The trade was a 9.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $284.91, for a total transaction of $156,130.68. Following the sale, the executive vice president directly owned 2,579 shares of the company’s stock, valued at $734,782.89. The trade was a 17.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 15,156 shares of company stock worth $4,095,496. Insiders own 0.84% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Evercore reissued an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Weiss Ratings restated a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. JPMorgan Chase & Co. raised their price target on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $308.00.

Labcorp Stock Performance

LH opened at $260.37 on Tuesday. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $21.35 billion, a PE ratio of 23.06, a P/E/G ratio of 1.82 and a beta of 0.91. The firm has a 50 day moving average of $263.75 and a two-hundred day moving average of $265.66. Labcorp Holdings Inc. has a 12-month low of $239.75 and a 12-month high of $293.72.

Labcorp (NYSE:LH) last posted its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, analysts anticipate that Labcorp Holdings Inc. will post 17.99 EPS for the current year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.